Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer

  1. Yang, J.C.-H.
  2. Zhou, C.
  3. Jänne, P.A.
  4. Ramalingam, S.S.
  5. Kim, T.M.
  6. Riely, G.J.
  7. Spira, A.I.
  8. Piotrowska, Z.
  9. Mekhail, T.
  10. Garcia Campelo, M.R.
  11. Felip, E.
  12. Bazhenova, L.
  13. Jin, S.
  14. Kaur, M.
  15. Diderichsen, P.M.
  16. Gupta, N.
  17. Bunn, V.
  18. Lin, J.
  19. N. Churchill, E.
  20. Mehta, M.
  21. Nguyen, D.
Revista:
Expert Review of Anticancer Therapy

ISSN: 1744-8328,  1473-7140

Ano de publicación: 2023

Volume: 23

Número: 1

Páxinas: 95-106

Tipo: Artigo

DOI: 10.1080/14737140.2023.2157815 GOOGLE SCHOLAR lock_openAcceso aberto editor

Obxectivos de Desenvolvemento Sustentable

Fonte de datos: Scopus